About this trial
The study would make it possible to document more explicitly the evolution of antibody titers at following a non-public vaccination over a large post-vaccination period in the French population .
Analysis of real-life data would enhance knowledge of vaccine response kinetics It would be useful to identify possible early declines requiring doses Similarly, by analyzing antibody kinetics by age, sex, and vaccination status, the would be possible to determine whether there are differences in the immune response between these different sub-groups. In addition, it would provide additional information to assess the real impact of these non-public vaccines in public health and guide vaccine policies.
Eligibility criteria
Qualifiers
Subject over 18 years of age
Subject presenting to the investigation centre as part of its usual management (prevention, screening, tracking)
Subject who has been vaccinated and/or wishes to be vaccinated
Subject able to understand the purpose of research that has given free and informed express consent
Disqualifiers
Protected subject: major under guardianship, curatorship or other legal protection, deprived of liberty by decision judicial or administrative
Trial design
Treatments tested in this trial
- Blood collection